T2-weighted magnetic resonance imaging of the liver: Evaluation of the effect in signal intensity after Gd-EOB-DTPA enhancement

Journal of Computer Assisted Tomography

Volumn 34, Issue 2, 2010, Pages 182-186

  Tamada, Tsutomu ^a   Ito, Katsuyoshi ^a   Yoshida, Koji ^a   Sone, Teruki ^a   Murakami, Koichi ^a   Kanki, Akihiko ^a   Watanabe, Shigeru ^a   Higashi, Hiroki ^a   Yamashita, Takenori ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Comparative studies; Contrast enhancement; Gd EOB DTPA; Liver; Magnetic resonance (MR); T2 weighted sequences

Indexed keywords

IMAGE ENHANCEMENT; MAGNETISM; RESONANCE;

COMPARATIVES STUDIES; CONTRAST ENHANCEMENT; DIETHYLENETRIAMINE PENTA-ACETIC ACIDS; GADOLINIA; GADOLINIA ETHOXYBENZYL DIETHYLENETRIAMINEPENTAACETIC ACID; MAGNETIC RESONANCE; SIGNAL INTENSITIES; T2 WEIGHTED; T2-WEIGHTED SEQUENCE; WEIGHTED SEQUENCES;

MAGNETIC RESONANCE IMAGING;

GADOXETIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; HUMAN; LIVER BLOOD VESSEL; LIVER PARENCHYMA; LIVER TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RADIOLOGICAL PARAMETERS;

EID: 77950347998     PISSN: 03638715     EISSN: None     Source Type: Journal    
DOI: 10.1097/RCT.0b013e3181bc961b     Document Type: Article

References (21)

1. Weinmann HJ, Schuhmann-Giampieri G, Schmitt-Willich H, et al. A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med. 1991;22:233-237.
2. Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, et al. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology. 1992;183:59-64.
3. Halavaara J, Breuer J, Ayuso C, et al. Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CTVa multicenter trial. J Comput Assist Tomogr. 2006;30:345-354.
4. Vogl TJ, Kümmel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology. 1996; 200:59-67.
5. Reimer P, Rummeny EJ, Daldrup HE, et al. Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging. Eur Radiol. 1997;7:275-280.
6. Huppertz A, Balzer T, Blakeborough A, et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology. 2004;230:266-275.
7. Hamm B, Staks T, Mühler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology. 1995;195:785-792.
8. Reimer P, Rummeny EJ, Shamsi K, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology. 1996;199:177-183.
9. Clément O, Mühler A, Vexler V, et al. Gadolinium- ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats. Invest Radiol. 1992;27:612-619.
10. Mühler A, Clément O, Vexler V, et al. Hepatobiliary enhancement with Gd-EOB-DTPA: comparison of spin-echo and STIR imaging for detection of experimental liver metastases. Radiology. 1992;184: 207-213.
11. Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acidYenhanced MR imaging: correlation with histopathologic findings and spiral CTVinitial observations. Radiology. 2005;234:468-478.
12. Hammerstingl R, Huppertz A, Breuer J, et al. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol. 2008;18:457-467.
13. Mitchell DG, Outwater EK, Vinitski S. Hybrid RARE: implementations for abdominal MR imaging. J Magn Reson Imaging. 1994;4:109-117.
14. Jeong YY, Mitchell DG, Holland GA. Liver lesion conspicuity: T2-weighted breath-hold fast spin-echo MR imaging before and after gadolinium enhancementVinitial experience. Radiology. 2001;219: 455-460.
15. Chang SD, Thoeni RF. Effect of T1 shortening on T2-weighted MRI sequences: comparison of hepatic mass conspicuity on images acquired before and after gadolinium enhancement. AJR Am J Roentgenol. 2008;190:1318-1323.
16. Nikolaou K, Schoenberg SO, Brix G, et al. Quantification of pulmonary blood flow and volume in healthy volunteers by dynamic contrast-enhanced magnetic resonance imaging using a parallel imaging technique. Invest Radiol. 2004;39:537-545.
17. Krinsky GA, Lee VS, Theise ND, et al. Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explantation correlation. Radiology. 2001;219: 445-454.
18. Matsui O, Kadoya M, Kameyama T, et al. Adenomatous hyperplastic nodules in the cirrhotic liver: differentiation from hepatocellular carcinoma with MR imaging. Radiology. 1989;173:123-126.
19. Earls JP, Theise ND, Weinreb JC, et al. Dysplastic nodules and hepatocellular carcinoma: thin-section MR imaging of explanted cirrhotic livers with pathologic correlation. Radiology. 1996;201: 207-214.
20. Martí-Bonmatí L, Masiá L, Casillas C, et al. Differentiation of healthy from cirrhotic livers. evaluation of parametric images after contrast administration in magnetic resonance imaging. Invest Radiol. 1996; 31:768-773.
21. Martí-Bonmatí L. MR contrast agents in hepatic cirrhosis and chronic hepatitis. Semin Ultrasound CT MR. 2002;23:101-113.